Relapse-Prevention Study With Levomilnacipran ER (F2695 SR) in Patients With Major Depressive Disorder
Public ClinicalTrials.gov record NCT01085812. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Randomized, Double-blind, Placebo-Controlled, Relapse-Prevention Study With F2695 SR in Patients With Major Depressive Disorder
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the safety and efficacy of Levomilnacipran ER relative to placebo in the prevention of depression relapse in patients with major depressive disorder (MDD).
Study identification
- NCT ID
- NCT01085812
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 734 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 28, 2010
- Primary completion
- Sep 30, 2011
- Completion
- Sep 30, 2011
- Last update posted
- Jan 12, 2020
2010 – 2011
United States locations
- U.S. sites
- 30
- U.S. states
- 14
- U.S. cities
- 29
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Forest Investigative Site #023 | Beverly Hills | California | 90210 | — |
| Forest Investigative Site #017 | Encino | California | 31316 | — |
| Forest Investigative Site #021 | Garden Grove | California | 92845 | — |
| Forest Investigative Site #025 | Newport Beach | California | 92660 | — |
| Forest Investigative Site #030 | Orange | California | 92868 | — |
| Forest Investigative Site #002 | San Diego | California | 92108 | — |
| Forest Investigative Site #003 | Sherman Oaks | California | 91403 | — |
| Forest Research Institute #001 | Bonita Springs | Florida | 34134 | — |
| Forest Investigative Site #015 | Fort Myers | Florida | 33912 | — |
| Forest Investigative Site #029 | Maitland | Florida | 32751 | — |
| Forest Investigative Site #005 | North Miami | Florida | 33161 | — |
| Forest Investigative Site #016 | Orlando | Florida | 32806 | — |
| Forest Investigative Site #004 | South Miami | Florida | 33143 | — |
| Forest Investigative Site #014 | Atlanta | Georgia | 30328 | — |
| Forest Investigative Site #022 | Chicago | Illinois | 60634 | — |
| Forest Investigative Site #006 | Chicago | Illinois | 60640 | — |
| Forest Investigative Site #009 | Prairie Village | Kansas | 66206 | — |
| Forest Investigative Site #013 | Baltimore | Maryland | 21208 | — |
| Forest Investigative Site #010 | Boston | Massachusetts | 02135 | — |
| Forest Investigative Site #012 | St Louis | Missouri | 63139 | — |
| Forest Investigative Site #011 | Staten Island | New York | 10312 | — |
| Forest Investigative Site #026 | Portland | Oregon | 97210 | — |
| Forest Investigative Site #008 | Bridgeville | Pennsylvania | 15017 | — |
| Forest Investigative Site #028 | Norristown | Pennsylvania | 19401 | — |
| Forest Investigative Site #020 | Philadelphia | Pennsylvania | 19139 | — |
| Forest Investigative Site #024 | Memphis | Tennessee | 38119 | — |
| Forest Investigative Site #007 | Dallas | Texas | 75231 | — |
| Forest Investigative Site #019 | San Antonio | Texas | 78229 | — |
| Forest Investigative Site #018 | Bellevue | Washington | 98007 | — |
| Forest Investigative Site #027 | Seattle | Washington | 98104 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 5 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01085812, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 12, 2020 · Synced Sep 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01085812 live on ClinicalTrials.gov.